392 related articles for article (PubMed ID: 29136407)
1. Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
Noble AR; Maitland NJ; Berney DM; Rumsby MG
Br J Cancer; 2018 Jan; 118(2):189-199. PubMed ID: 29136407
[TBL] [Abstract][Full Text] [Related]
2. Phospholipase D2 in prostate cancer: protein expression changes with Gleason score.
Noble AR; Hogg K; Suman R; Berney DM; Bourgoin S; Maitland NJ; Rumsby MG
Br J Cancer; 2019 Dec; 121(12):1016-1026. PubMed ID: 31673104
[TBL] [Abstract][Full Text] [Related]
3. Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6.
Schmitt J; Noble A; Otsuka M; Berry P; Maitland NJ; Rumsby MG
Br J Cancer; 2014 Oct; 111(8):1646-56. PubMed ID: 25137020
[TBL] [Abstract][Full Text] [Related]
4. Increased phospholipase D activity contributes to tumorigenesis in prostate cancer cell models.
Borel M; Cuvillier O; Magne D; Mebarek S; Brizuela L
Mol Cell Biochem; 2020 Oct; 473(1-2):263-279. PubMed ID: 32661773
[TBL] [Abstract][Full Text] [Related]
5. The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells.
Stricker HM; Rommerswinkel N; Keil S; Gnoth SA; Niggemann B; Dittmar T
Cell Commun Signal; 2021 Apr; 19(1):43. PubMed ID: 33832505
[TBL] [Abstract][Full Text] [Related]
6. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion.
Burkhardt U; Beyer S; Klein J
Eur J Pharmacol; 2015 Aug; 761():398-404. PubMed ID: 25967349
[TBL] [Abstract][Full Text] [Related]
7. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer-derived exosomes promote osteoblast differentiation and activity through phospholipase D2.
Borel M; Lollo G; Magne D; Buchet R; Brizuela L; Mebarek S
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165919. PubMed ID: 32800947
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
Lewis JA; Scott SA; Lavieri R; Buck JR; Selvy PE; Stoops SL; Armstrong MD; Brown HA; Lindsley CW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1916-20. PubMed ID: 19268584
[TBL] [Abstract][Full Text] [Related]
11. Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.
Festuccia C; Gravina GL; Mancini A; Muzi P; Cesare ED; Kirk R; Smith M; Hughes S; Gibson R; Lian LY; Ricevuto E; Carnell AJ
Anticancer Agents Med Chem; 2014; 14(7):1031-41. PubMed ID: 24712326
[TBL] [Abstract][Full Text] [Related]
12. Two sites of action for PLD2 inhibitors: The enzyme catalytic center and an allosteric, phosphoinositide biding pocket.
Ganesan R; Mahankali M; Alter G; Gomez-Cambronero J
Biochim Biophys Acta; 2015 Mar; 1851(3):261-72. PubMed ID: 25532944
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
14. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
15. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
[TBL] [Abstract][Full Text] [Related]
16. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
Festuccia C; Angelucci A; Gravina GL; Muzi P; Vicentini C; Bologna M
J Cancer Res Clin Oncol; 2005 Apr; 131(4):243-54. PubMed ID: 15650886
[TBL] [Abstract][Full Text] [Related]
17. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
18. Autoregulation of phospholipase D activity is coupled to selective induction of phospholipase D1 expression to promote invasion of breast cancer cells.
Kang DW; Park MH; Lee YJ; Kim HS; Lindsley CW; Alex Brown H; Min do S
Int J Cancer; 2011 Feb; 128(4):805-16. PubMed ID: 20473892
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells.
Gravina GL; Ranieri G; Muzi P; Marampon F; Mancini A; Di Pasquale B; Di Clemente L; Dolo V; D'Alessandro AM; Festuccia C
Oncol Rep; 2013 Mar; 29(3):1189-95. PubMed ID: 23254386
[TBL] [Abstract][Full Text] [Related]
20. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
